Nicholas Bagley, JD, says immediate effects of the ruling have been modest so far.
Nicholas Bagley, JD, professor at Michigan Law, University of Michigan, spoke to The American Journal of Managed Care® about the Braidwood v Becerra ruling and the uncertainty around decisions that will follow if it is upheld.
Transcript
What are the immediate effects of the ruling in Braidwood v Becerra?
The decision isn't going to have an immediate or dramatic effect, and that's for a couple of reasons. First, and most importantly, I think most employers and insurers are kind of in a watching and waiting mood. They're looking to see what's going to happen with this case on appeal. I think very few, if any, [are going to be making serious] or sweeping changes to their coverage choices. That may actually end up being the case, even if the plaintiffs win—that there will be a relatively small number of employers that really change up what they're doing. But there's a fair amount of uncertainty around that and what kinds of decisions they’ll make if the decision is eventually upheld.
The government has already appealed the judge's decision and asked the US Court of Appeals for the Fifth Circuit to put a hold on his decision while the Fifth Circuit considers it. That effort to get a state pending appeal has been opposed by the plaintiffs who are also going to take an appeal of their own. But in the meantime, I think, right now, we are mostly in a waiting mode. The longer this drags on, the more employers and insurers may decide that they want to try to change their offerings. But for now, it seems that their response has been pretty modest.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More